Investor Class Action Filed Against Nektar Therapeutics for Securities Fraud Violations
Company Name: Nektar Therapeutics
Court: United States District Court for the Northern District of California
Case Number: 18-cv-06607
Judge: The Hon. Haywood Stirling Gilliam Jr.
Class period: Between January 10, 2017 and September 28, 2018
Security Type: Common stock

Case Background:

On October 30, 2018, the initial complaint in this securities class action was filed against Nektar Therapeutics (“Nektar” or the “Company”), and certain of Nektar’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act.  

The complaint alleged that throughout the class period, the defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, the defendants made false and/or misleading statements and/or failed to disclose that: (i) prior studies which attempted to pegylate IL-2 failed; (ii) NKTR-214’s extended half-life was unlikely to result in efficacy and created additional high-dosing safety concerns; (iii) NKTR-214 was less effective than IL-2 alone; (iv) the combination of NKTR-214 with nivolumab has not yet demonstrated significant positive results; and (v) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.

This securities class action case was brought on behalf of those who purchased or otherwise acquired Nektar common stock between January 10, 2017 and September 28, 2018, inclusive.

Current Status of Case:

On July 13, 2020, the Court granted the defendants’ motion to dismiss the lead plaintiffs’ amended complaint without prejudice and with leave to amend.  On August 10, 2020, the lead plaintiffs filed a second consolidated amended complaint.  The defendants filed a motion to dismiss the second consolidated amended complaint on September 17, 2020 and that motion has now been fully briefed before the Court pending its decision.

If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at

Please complete this form relating to your transactions in Nektar Therapeutics (Nasdaq: NKTR) securities between January 10, 2017 and September 28, 2018, both dates inclusive (the “Class Period”).

You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 844.887.9500, or you may submit your information via email at, or you may click here to print a PDF of this form.

* Denotes required field
# of Shares
Price per Share
Principal Amount
Amount Paid
Series or CUSIP
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Nektar Therapeutics (2018) prior to the Class Period?
Are you a current or former employee of Nektar Therapeutics (2018)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC
I would like to receive
new case alerts by email